Dietary Fats and Cardio-Metabolic Outcomes in a Cohort of Italian Adults.
dietary fats
fat
monounsaturated fats
polyunsaturated fats
saturated fats
short-chain fatty acids
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
14 Oct 2022
14 Oct 2022
Historique:
received:
12
09
2022
revised:
08
10
2022
accepted:
11
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Dietary fats, and especially saturated fatty acid (SFA), have been blamed for being the culprit in the dramatic increase in obesity and its associated diseases. However multiple systematic reviews and recent meta-analyses do not support the association between SFA and cardiovascular diseases. Thus, the objective of this study was to test whether specific types and subtypes of dietary fats are associated with metabolic outcomes in a cohort of Italian adults. Nutritional and demographic data of 1936 adults living in the south of Italy were examined. Food frequency questionnaires (FFQs) were administered to assess the intake of total dietary fat and each specific class of dietary fat, such as SFA, monounsaturated fatty acid (MUFA) and polyunsaturated fatty acid (PUFA). The intake of fatty acids was also examined according to the carbon-chain length of each individual class. Cases of hypertension, type-2 diabetes and dyslipidemias were collected from previous doctor-confirmed diagnosis records (or direct measurement of blood pressure). After adjustment for potential confounding factors, individuals reporting higher intakes of total and saturated fats were associated with lower likelihood of having hypertension (odds ratio (OR) = 0.57, 95% CI: 0.35, 0.91 and OR = 0.55, 95% CI: 0.34, 0.89, respectively). Moreover, higher intake of short-chain saturated fatty acids (SCSFAs) and medium-chain saturated fatty acids (MCSFAs) was inversely associated with dyslipidemia and diabetes (OR = 0.43, 95% CI: 0.23, 0.82 and OR = 0.25, 95% CI: 0.09, 0.72, respectively). Among MUFAs, C18:1 was inversely associated with hypertension and diabetes (OR = 0.52, 95% CI: 0.30, 0.92 and OR = 0.21, 95% CI: 0.07, 0.67, respectively), while C14:1 intake was inversely associated only with hypertension (OR = 0.57, 95% CI: 0.37, 0.88). In contrast, C20:1 intake was associated with dyslipidemia (OR = 3.35, 95% CI: 1.33, 8.42). Regarding PUFA, C18:2 and 20:5 were inversely associated with hypertension (OR = 0.33, 95% CI: 0.18, 0.60 and OR = 0.30, 95% CI: 0.10, 0.89, respectively). The consumption of SFA does not seem to be harmful to cardio-metabolic health and, on the contrary, SCSFA may exert beneficial effects. Further studies are needed to clearly validate the results of the present study.
Sections du résumé
BACKGROUND
BACKGROUND
Dietary fats, and especially saturated fatty acid (SFA), have been blamed for being the culprit in the dramatic increase in obesity and its associated diseases. However multiple systematic reviews and recent meta-analyses do not support the association between SFA and cardiovascular diseases. Thus, the objective of this study was to test whether specific types and subtypes of dietary fats are associated with metabolic outcomes in a cohort of Italian adults.
METHODS
METHODS
Nutritional and demographic data of 1936 adults living in the south of Italy were examined. Food frequency questionnaires (FFQs) were administered to assess the intake of total dietary fat and each specific class of dietary fat, such as SFA, monounsaturated fatty acid (MUFA) and polyunsaturated fatty acid (PUFA). The intake of fatty acids was also examined according to the carbon-chain length of each individual class. Cases of hypertension, type-2 diabetes and dyslipidemias were collected from previous doctor-confirmed diagnosis records (or direct measurement of blood pressure).
RESULTS
RESULTS
After adjustment for potential confounding factors, individuals reporting higher intakes of total and saturated fats were associated with lower likelihood of having hypertension (odds ratio (OR) = 0.57, 95% CI: 0.35, 0.91 and OR = 0.55, 95% CI: 0.34, 0.89, respectively). Moreover, higher intake of short-chain saturated fatty acids (SCSFAs) and medium-chain saturated fatty acids (MCSFAs) was inversely associated with dyslipidemia and diabetes (OR = 0.43, 95% CI: 0.23, 0.82 and OR = 0.25, 95% CI: 0.09, 0.72, respectively). Among MUFAs, C18:1 was inversely associated with hypertension and diabetes (OR = 0.52, 95% CI: 0.30, 0.92 and OR = 0.21, 95% CI: 0.07, 0.67, respectively), while C14:1 intake was inversely associated only with hypertension (OR = 0.57, 95% CI: 0.37, 0.88). In contrast, C20:1 intake was associated with dyslipidemia (OR = 3.35, 95% CI: 1.33, 8.42). Regarding PUFA, C18:2 and 20:5 were inversely associated with hypertension (OR = 0.33, 95% CI: 0.18, 0.60 and OR = 0.30, 95% CI: 0.10, 0.89, respectively).
CONCLUSIONS
CONCLUSIONS
The consumption of SFA does not seem to be harmful to cardio-metabolic health and, on the contrary, SCSFA may exert beneficial effects. Further studies are needed to clearly validate the results of the present study.
Identifiants
pubmed: 36296979
pii: nu14204294
doi: 10.3390/nu14204294
pmc: PMC9608185
pii:
doi:
Substances chimiques
Dietary Fats
0
Fatty Acids
0
Fatty Acids, Unsaturated
0
Fatty Acids, Monounsaturated
0
Fatty Acids, Volatile
0
Carbon
7440-44-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : King Saud University
ID : Distinguished Scientist Fellowship Program (DSFP)
Organisme : University of Catania
ID : Piano di incentivi per la ricerca di Ateneo 2020/2022
Organisme : European Union
ID : FSE-REACT-EU, PON Research and Innovation 2014-2020 DM1062/2021; CUP: E65F21002560001
Références
Obes Rev. 2016 Apr;17(4):297-312
pubmed: 26712364
Nutr Metab Cardiovasc Dis. 2019 Sep;29(9):887-905
pubmed: 31377181
Int J Food Sci Nutr. 2022 Sep;73(6):726-737
pubmed: 35291893
J Nutr Biochem. 2016 Oct;36:1-20
pubmed: 27692243
BMJ. 2015 Aug 11;351:h3978
pubmed: 26268692
Circulation. 2017 Jul 18;136(3):e1-e23
pubmed: 28620111
Nutr Metab (Lond). 2011 Jun 10;8:36
pubmed: 21663641
Am J Clin Nutr. 2003 May;77(5):1146-55
pubmed: 12716665
Nutrients. 2021 Sep 22;13(10):
pubmed: 34684304
Int J Food Sci Nutr. 2017 Aug;68(5):577-586
pubmed: 27919168
Int J Environ Res Public Health. 2021 Feb 14;18(4):
pubmed: 33672852
Arterioscler Thromb. 1994 Apr;14(4):567-75
pubmed: 8148355
Cochrane Database Syst Rev. 2020 Aug 21;8:CD011737
pubmed: 32827219
Mech Ageing Dev. 2017 Jul;165(Pt B):129-138
pubmed: 28038993
Am J Clin Nutr. 2010 Mar;91(3):535-46
pubmed: 20071648
Hypertension. 2008 Aug;52(2):408-14
pubmed: 18606902
Am J Clin Nutr. 2010 Jan;91(1):46-63
pubmed: 19939984
Oxid Med Cell Longev. 2014;2014:313570
pubmed: 24757497
Am J Clin Nutr. 2009 May;89(5):1425-32
pubmed: 19211817
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
Lipids Health Dis. 2019 Apr 6;18(1):91
pubmed: 30954077
BMJ Evid Based Med. 2021 Feb;26(1):3-7
pubmed: 31142556
Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):316-22
pubmed: 9484999
Nutrients. 2022 Mar 08;14(6):
pubmed: 35334794
Lancet Diabetes Endocrinol. 2017 Dec;5(12):965-974
pubmed: 29032079
PLoS Med. 2016 Jul 19;13(7):e1002087
pubmed: 27434027
Transl Res. 2021 Nov;237:16-30
pubmed: 33775867
Int J Food Sci Nutr. 2020 Mar;71(2):138-151
pubmed: 31199182
Am J Clin Nutr. 2001 Jun;73(6):1019-26
pubmed: 11382654
BMJ. 2016 Nov 23;355:i5796
pubmed: 27881409
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
BMJ. 2018 Jun 13;361:k2139
pubmed: 29898882
Int J Food Sci Nutr. 2015;66(6):611-22
pubmed: 26307560
Nutr Rev. 2020 Nov 1;78(11):952-968
pubmed: 32299100
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
J Clin Lipidol. 2017 Jan - Feb;11(1):126-135.e5
pubmed: 28391879
J Am Heart Assoc. 2022 Jun 7;11(11):e025071
pubmed: 35647665
Crit Rev Food Sci Nutr. 2019;59(20):3380-3393
pubmed: 29993265
Int J Food Sci Nutr. 2015;66(4):426-38
pubmed: 25830946
JAMA. 2015 Jun 23-30;313(24):2421-2
pubmed: 26103023
Lancet. 2017 Nov 4;390(10107):2050-2062
pubmed: 28864332
Ann Surg. 2003 Feb;237(2):246-55
pubmed: 12560783
Adv Nutr. 2015 May 15;6(3):293S-301S
pubmed: 25979502
Exp Biol Med (Maywood). 2008 Jun;233(6):674-88
pubmed: 18408140
Clin Exp Pharmacol Physiol. 2006 Sep;33(9):842-6
pubmed: 16922818
J Nutr Biochem. 2005 Jun;16(6):375-82
pubmed: 15936650
NCHS Data Brief. 2017 Dec;(293):1-8
pubmed: 29319473
Nutr Metab (Lond). 2018 Jun 05;15:37
pubmed: 29991957
Biomolecules. 2022 May 24;12(6):
pubmed: 35740864
PLoS Med. 2010 Mar 23;7(3):e1000252
pubmed: 20351774
Nutr Metab Cardiovasc Dis. 2014 Jun;24(6):606-13
pubmed: 24602606
J Am Heart Assoc. 2014 Oct 15;3(5):e001095
pubmed: 25319187
Int J Food Sci Nutr. 2021 Jun;72(4):429-431
pubmed: 33980125
Lipids. 2010 Nov;45(11):997-1009
pubmed: 20811782
BMJ Open Diabetes Res Care. 2019 Feb 8;7(1):e000585
pubmed: 30899527
Adv Food Nutr Res. 2012;65:211-22
pubmed: 22361189
Int J Food Sci Nutr. 2020 Sep;71(6):668-677
pubmed: 31964201
Int J Food Sci Nutr. 2016 Nov;67(7):857-64
pubmed: 27333325
J Immunol. 2013 Jul 15;191(2):527-32
pubmed: 23825387
Nutrients. 2020 Dec 09;12(12):
pubmed: 33317164